Trial · NCT07224360
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360, Phase 2, Recruiting, CSL Behring
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD). Trials, record NCT07224360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07224360
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- NCT number
- NCT07224360
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 63 participants, estimated
- Lead sponsor
- CSL Behring
- Conditions
- Sickle Cell Disease
- Interventions
- Anumigilimab, Placebo
- First posted
- 2025-11-04
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP) | From baseline up to Week 75 | |
| Primary | Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IP | From baseline up to Week 75 | |
| Primary | Number of participants with Adverse Events of Special Interest (AESI) | From baseline up to Week 75 | The following AEs are to be reported as AESI: neutropenia (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade 3 or 4), severe infection and neutropenic fever. |
| Primary | Percentage of participants with AESI | From baseline up to Week 75 | The following AEs are to be reported as AESI: neutropenia (CTCAE Grade 3 or 4), severe infection and neutropenic fever. |
| Primary | Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signs | From baseline up to Week 75 | |
| Primary | Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signs | From baseline up to Week 75 | |
| Secondary | Serum concentration of Anumigilimab | From the first dose of anumigilimab to Week 65 | |
| Secondary | Annualized rate of Vaso-occlusive crisis (VOC) (medical facility) | During the maintenance period from Week 13 to Week 65 | VOC (medical facility) is defined as VOC that results in a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07224360
GET https://conductscience.org/api/trials/v1/NCT07224360/registered